Related references
Note: Only part of the references are listed.CD14+ intestinal macrophages contribute to the pathogenesis of Crohnʼs disease via IL-23/IFN-gamma axis.
T Hisamatsu et al.
INFLAMMATORY BOWEL DISEASES (2012)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
Julia Dunne et al.
PEDIATRICS (2011)
Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
Jeffrey S. Hyams et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBD
Cary G. Sauer et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2009)
Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter study
Dan Turner et al.
GASTROENTEROLOGY (2007)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Ethical concerns regarding guidelines for the conduct of clinical research on children
SD Edwards et al.
JOURNAL OF MEDICAL ETHICS (2005)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Share Paper
